Nutrition for Cancer Survivors.
Cancer is a leading cause of morbidity and mortality worldwide with tremendous burden for the individual and the society [...]....
Protein-arginine N-methyltransferases : Questions médicales fréquentes
Questions fréquentes et termes MeSH associés
Diagnostic 5
#1
Comment diagnostiquer une dysfonction des N-méthyltransférases ?
Des tests génétiques et des analyses biochimiques peuvent être utilisés pour diagnostiquer.
#2
Quels tests sont utilisés pour évaluer l'activité enzymatique ?
Des tests enzymatiques spécifiques mesurent l'activité des N-méthyltransférases dans les échantillons.
#3
Y a-t-il des biomarqueurs associés à ces enzymes ?
Des biomarqueurs comme la méthylation de l'arginine peuvent indiquer une activité enzymatique.
#4
Quels symptômes peuvent indiquer un problème enzymatique ?
Des symptômes variés comme des troubles neurologiques ou immunitaires peuvent survenir.
#5
Comment les tests génétiques aident-ils au diagnostic ?
Ils identifient des mutations spécifiques dans les gènes codant pour ces enzymes.
Symptômes 5
#1
Quels sont les symptômes d'une carence en N-méthyltransférases ?
Les symptômes incluent fatigue, troubles cognitifs et anomalies immunitaires.
#2
Les troubles de l'humeur sont-ils liés à ces enzymes ?
Oui, des déséquilibres peuvent affecter l'humeur et contribuer à des troubles psychiatriques.
#3
Peut-on observer des symptômes neurologiques ?
Oui, des troubles neurologiques comme des convulsions peuvent être présents.
#4
Y a-t-il des symptômes spécifiques chez les enfants ?
Les enfants peuvent présenter des retards de développement et des troubles d'apprentissage.
#5
Comment les symptômes varient-ils selon l'âge ?
Les symptômes peuvent être plus prononcés chez les jeunes enfants et les personnes âgées.
Prévention 5
#1
Comment prévenir les troubles liés aux N-méthyltransférases ?
Une alimentation équilibrée et un mode de vie sain peuvent aider à prévenir ces troubles.
#2
Y a-t-il des mesures préventives spécifiques ?
Des dépistages précoces et des conseils génétiques peuvent être bénéfiques.
#3
L'éducation sur la santé est-elle importante ?
Oui, sensibiliser les patients et les familles peut aider à identifier les symptômes tôt.
#4
Les vaccinations jouent-elles un rôle préventif ?
Certaines vaccinations peuvent prévenir des infections qui aggravent les symptômes.
#5
Comment le suivi médical aide-t-il à la prévention ?
Un suivi régulier permet de surveiller l'état de santé et d'ajuster les traitements.
Traitements 5
#1
Quels traitements existent pour les dysfonctionnements enzymatiques ?
Les traitements peuvent inclure des suppléments nutritionnels et des thérapies ciblées.
#2
Les médicaments peuvent-ils aider à réguler ces enzymes ?
Oui, certains médicaments peuvent moduler l'activité des N-méthyltransférases.
#3
Y a-t-il des thérapies géniques disponibles ?
Des recherches sont en cours sur les thérapies géniques pour corriger les mutations.
#4
Comment la nutrition influence-t-elle le traitement ?
Une alimentation riche en nutriments peut soutenir la fonction enzymatique.
#5
Les traitements sont-ils personnalisés ?
Oui, les traitements peuvent être adaptés en fonction des besoins individuels du patient.
Complications 5
#1
Quelles complications peuvent survenir avec ces troubles ?
Des complications neurologiques, immunitaires et métaboliques peuvent se développer.
#2
Les troubles cardiovasculaires sont-ils possibles ?
Oui, des déséquilibres peuvent augmenter le risque de maladies cardiovasculaires.
#3
Comment les complications affectent-elles la qualité de vie ?
Elles peuvent entraîner des limitations fonctionnelles et des besoins de soins accrus.
#4
Y a-t-il des complications à long terme ?
Oui, des complications chroniques peuvent affecter la santé globale et le bien-être.
#5
Les complications peuvent-elles être évitées ?
Certaines complications peuvent être évitées par un traitement précoce et approprié.
Facteurs de risque 5
#1
Quels sont les facteurs de risque associés ?
Les facteurs incluent des antécédents familiaux, des mutations génétiques et des carences nutritionnelles.
#2
L'environnement joue-t-il un rôle ?
Oui, des facteurs environnementaux comme la pollution peuvent influencer la fonction enzymatique.
#3
Le mode de vie affecte-t-il le risque ?
Un mode de vie sédentaire et une mauvaise alimentation augmentent le risque de troubles.
#4
Les infections peuvent-elles être un facteur de risque ?
Certaines infections peuvent exacerber les symptômes et augmenter le risque de complications.
#5
Y a-t-il des groupes à risque spécifiques ?
Les personnes avec des antécédents familiaux ou des troubles métaboliques sont plus à risque.
Contenu validé par Dr Olivier Menir
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 23/03/2025
Contenu vérifié selon les dernières recommandations médicales
Auteurs principaux
Y George Zheng
4 publications dans cette catégorie
Affiliations :
- Department of Pharmaceutical and Biomedical Sciences, University of Georgia, Athens, GA 30602, United States. yzheng@uga.edu.
Publications dans "Protein-arginine N-methyltransferases" :
-
Protein arginine methyltransferase 6 is a novel substrate of protein arginine methyltransferase 1.
World journal of biological chemistry
-
The macromolecular complexes of histones affect protein arginine methyltransferase activities.
The Journal of biological chemistry 2021-09-06
-
Protein arginine methyltransferases: insights into the enzyme structure and mechanism at the atomic level.
Cellular and molecular life sciences : CMLS 2019-05-23
-
Hetero-oligomeric interaction as a new regulatory mechanism for protein arginine methyltransferases.
Biochemical Society transactions 2024-09-26
Adam Frankel
4 publications dans cette catégorie
Affiliations :
- Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, British Columbia, Canada. Electronic address: adam.frankel@ubc.ca.
Publications dans "Protein-arginine N-methyltransferases" :
-
Protein arginine N-methyltransferase 2 plays a noncatalytic role in the histone methylation activity of PRMT1.
The Journal of biological chemistry 2023-10-19
-
The application of differential scanning fluorimetry in exploring bisubstrate binding to protein arginine N-methyltransferase 1.
Methods (San Diego, Calif.) 2019-11-11
-
Protein arginine N-methyltransferase activity determination with filter binding and phosphor screening (FBAPS) assay.
Analytical biochemistry 2022-06-13
-
Protein Arginine Methyltransferases in Cardiovascular and Neuronal Function.
Molecular neurobiology 2019-12-10
Alessandra Feoli
3 publications dans cette catégorie
Affiliations :
- Department of Pharmacy, Epigenetic Med Chem Lab, University of Salerno, via Giovanni Paolo II 132, Fisciano ,I-84084 SA Italy.
Publications dans "Protein-arginine N-methyltransferases" :
-
Identification of a Protein Arginine Methyltransferase 7 (PRMT7)/Protein Arginine Methyltransferase 9 (PRMT9) Inhibitor.
Journal of medicinal chemistry 2023-08-10
-
Turning Nonselective Inhibitors of Type I Protein Arginine Methyltransferases into Potent and Selective Inhibitors of Protein Arginine Methyltransferase 4 through a Deconstruction-Reconstruction and Fragment-Growing Approach.
Journal of medicinal chemistry 2022-04-28
-
Prodrug Approach to Exploit (S) Alanine as Arginine Mimic Moiety in the Development of Protein Arginine Methyltransferase 4 Inhibitors.
ChemMedChem 2024-05-16
Giulia Iannelli
3 publications dans cette catégorie
Affiliations :
- Department of Pharmacy, Epigenetic Med Chem Lab, University of Salerno, via Giovanni Paolo II 132, Fisciano ,I-84084 SA Italy.
- PhD Program in Drug Discovery and Development, University of Salerno, via Giovanni Paolo II 132, Fisciano ,I-84084 SA Italy.
Publications dans "Protein-arginine N-methyltransferases" :
-
Identification of a Protein Arginine Methyltransferase 7 (PRMT7)/Protein Arginine Methyltransferase 9 (PRMT9) Inhibitor.
Journal of medicinal chemistry 2023-08-10
-
Turning Nonselective Inhibitors of Type I Protein Arginine Methyltransferases into Potent and Selective Inhibitors of Protein Arginine Methyltransferase 4 through a Deconstruction-Reconstruction and Fragment-Growing Approach.
Journal of medicinal chemistry 2022-04-28
-
Prodrug Approach to Exploit (S) Alanine as Arginine Mimic Moiety in the Development of Protein Arginine Methyltransferase 4 Inhibitors.
ChemMedChem 2024-05-16
Alessandra Cipriano
3 publications dans cette catégorie
Affiliations :
- Department of Pharmacy, Epigenetic Med Chem Lab, University of Salerno, via Giovanni Paolo II 132, Fisciano ,I-84084 SA Italy.
Publications dans "Protein-arginine N-methyltransferases" :
-
Identification of a Protein Arginine Methyltransferase 7 (PRMT7)/Protein Arginine Methyltransferase 9 (PRMT9) Inhibitor.
Journal of medicinal chemistry 2023-08-10
-
Turning Nonselective Inhibitors of Type I Protein Arginine Methyltransferases into Potent and Selective Inhibitors of Protein Arginine Methyltransferase 4 through a Deconstruction-Reconstruction and Fragment-Growing Approach.
Journal of medicinal chemistry 2022-04-28
-
Prodrug Approach to Exploit (S) Alanine as Arginine Mimic Moiety in the Development of Protein Arginine Methyltransferase 4 Inhibitors.
ChemMedChem 2024-05-16
Ciro Milite
3 publications dans cette catégorie
Affiliations :
- Department of Pharmacy, Epigenetic Med Chem Lab, University of Salerno, via Giovanni Paolo II 132, Fisciano ,I-84084 SA Italy.
Publications dans "Protein-arginine N-methyltransferases" :
-
Identification of a Protein Arginine Methyltransferase 7 (PRMT7)/Protein Arginine Methyltransferase 9 (PRMT9) Inhibitor.
Journal of medicinal chemistry 2023-08-10
-
Turning Nonselective Inhibitors of Type I Protein Arginine Methyltransferases into Potent and Selective Inhibitors of Protein Arginine Methyltransferase 4 through a Deconstruction-Reconstruction and Fragment-Growing Approach.
Journal of medicinal chemistry 2022-04-28
-
Prodrug Approach to Exploit (S) Alanine as Arginine Mimic Moiety in the Development of Protein Arginine Methyltransferase 4 Inhibitors.
ChemMedChem 2024-05-16
Monica Viviano
3 publications dans cette catégorie
Affiliations :
- Department of Pharmacy, Epigenetic Med Chem Lab, University of Salerno, via Giovanni Paolo II 132, Fisciano ,I-84084 SA Italy.
Publications dans "Protein-arginine N-methyltransferases" :
-
Identification of a Protein Arginine Methyltransferase 7 (PRMT7)/Protein Arginine Methyltransferase 9 (PRMT9) Inhibitor.
Journal of medicinal chemistry 2023-08-10
-
Turning Nonselective Inhibitors of Type I Protein Arginine Methyltransferases into Potent and Selective Inhibitors of Protein Arginine Methyltransferase 4 through a Deconstruction-Reconstruction and Fragment-Growing Approach.
Journal of medicinal chemistry 2022-04-28
-
Prodrug Approach to Exploit (S) Alanine as Arginine Mimic Moiety in the Development of Protein Arginine Methyltransferase 4 Inhibitors.
ChemMedChem 2024-05-16
Sabrina Castellano
3 publications dans cette catégorie
Affiliations :
- Department of Pharmacy, Epigenetic Med Chem Lab, University of Salerno, via Giovanni Paolo II 132, Fisciano ,I-84084 SA Italy.
Publications dans "Protein-arginine N-methyltransferases" :
-
Identification of a Protein Arginine Methyltransferase 7 (PRMT7)/Protein Arginine Methyltransferase 9 (PRMT9) Inhibitor.
Journal of medicinal chemistry 2023-08-10
-
Turning Nonselective Inhibitors of Type I Protein Arginine Methyltransferases into Potent and Selective Inhibitors of Protein Arginine Methyltransferase 4 through a Deconstruction-Reconstruction and Fragment-Growing Approach.
Journal of medicinal chemistry 2022-04-28
-
Prodrug Approach to Exploit (S) Alanine as Arginine Mimic Moiety in the Development of Protein Arginine Methyltransferase 4 Inhibitors.
ChemMedChem 2024-05-16
Gianluca Sbardella
3 publications dans cette catégorie
Affiliations :
- Department of Pharmacy, Epigenetic Med Chem Lab, University of Salerno, via Giovanni Paolo II 132, Fisciano ,I-84084 SA Italy.
Publications dans "Protein-arginine N-methyltransferases" :
-
Identification of a Protein Arginine Methyltransferase 7 (PRMT7)/Protein Arginine Methyltransferase 9 (PRMT9) Inhibitor.
Journal of medicinal chemistry 2023-08-10
-
Turning Nonselective Inhibitors of Type I Protein Arginine Methyltransferases into Potent and Selective Inhibitors of Protein Arginine Methyltransferase 4 through a Deconstruction-Reconstruction and Fragment-Growing Approach.
Journal of medicinal chemistry 2022-04-28
-
Prodrug Approach to Exploit (S) Alanine as Arginine Mimic Moiety in the Development of Protein Arginine Methyltransferase 4 Inhibitors.
ChemMedChem 2024-05-16
Rong Huang
3 publications dans cette catégorie
Affiliations :
- Department of Medicinal Chemistry and Molecular Pharmacology, Center for Cancer Research, Institute for Drug Discovery, Purdue University, West Lafayette, IN 47907, United States.
Publications dans "Protein-arginine N-methyltransferases" :
-
Non-Histone Arginine Methylation by Protein Arginine Methyltransferases.
Current protein & peptide science
-
A Pan-Inhibitor for Protein Arginine Methyltransferase Family Enzymes.
Biomolecules 2021-06-08
-
Chemical Biology of Protein N-Terminal Methyltransferases.
Chembiochem : a European journal of chemical biology 2019-02-13
Shougang Zhuang
3 publications dans cette catégorie
Affiliations :
- Department of Medicine, Rhode Island Hospital and Alpert Medical School, Brown University, Providence, RI, U.S.A.
- Department of Nephrology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
Publications dans "Protein-arginine N-methyltransferases" :
-
The role of protein arginine methyltransferases in kidney diseases.
Clinical science (London, England : 1979)
-
Protein arginine methyltransferases in renal development, injury, repair, and fibrosis.
Frontiers in pharmacology 2023-02-03
-
The Role and Mechanism of Lysine Methyltransferase and Arginine Methyltransferase in Kidney Diseases.
Frontiers in pharmacology 2022-04-26
Jong-Sun Kang
3 publications dans cette catégorie
Affiliations :
- Department of Molecular Cell Biology, School of Medicine, Sungkyunkwan University, Suwon 16419, Korea.
- Single Cell Network Research Center, Sungkyunkwan University, Suwon 16419, Korea.
Publications dans "Protein-arginine N-methyltransferases" :
-
Protein Arginine Methyltransferases in Neuromuscular Function and Diseases.
Cells 2022-01-21
-
Role of Protein Arginine Methyltransferases and Inflammation in Muscle Pathophysiology.
Frontiers in physiology 2021-08-19
-
Protein Arginine Methyltransferases: Emerging Targets in Cardiovascular and Metabolic Disease.
Diabetes & metabolism journal 2024-07-24
Giuliana Sarno
2 publications dans cette catégorie
Affiliations :
- Department of Pharmacy, Epigenetic Med Chem Lab, University of Salerno, via Giovanni Paolo II 132, Fisciano ,I-84084 SA Italy.
- PhD Program in Drug Discovery and Development, University of Salerno, via Giovanni Paolo II 132, Fisciano ,I-84084 SA Italy.
Publications dans "Protein-arginine N-methyltransferases" :
-
Identification of a Protein Arginine Methyltransferase 7 (PRMT7)/Protein Arginine Methyltransferase 9 (PRMT9) Inhibitor.
Journal of medicinal chemistry 2023-08-10
-
Prodrug Approach to Exploit (S) Alanine as Arginine Mimic Moiety in the Development of Protein Arginine Methyltransferase 4 Inhibitors.
ChemMedChem 2024-05-16
Steven G Clarke
2 publications dans cette catégorie
Affiliations :
- Department of Chemistry and Biochemistry, and the Molecular Biology Institute, University of California, Los Angeles, California 90095, United States.
Publications dans "Protein-arginine N-methyltransferases" :
-
Identification of a Protein Arginine Methyltransferase 7 (PRMT7)/Protein Arginine Methyltransferase 9 (PRMT9) Inhibitor.
Journal of medicinal chemistry 2023-08-10
-
PRMT7 as a unique member of the protein arginine methyltransferase family: A review.
Archives of biochemistry and biophysics 2019-02-22
Yandong Lai
2 publications dans cette catégorie
Affiliations :
- Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Publications dans "Protein-arginine N-methyltransferases" :
Xiuying Li
2 publications dans cette catégorie
Affiliations :
- Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
- Veterans Affairs Pittsburgh Healthcare system, Pittsburgh, Pennsylvania, USA.
Publications dans "Protein-arginine N-methyltransferases" :
Tiao Li
2 publications dans cette catégorie
Affiliations :
- Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Publications dans "Protein-arginine N-methyltransferases" :
Toru Nyunoya
2 publications dans cette catégorie
Affiliations :
- Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
- Veterans Affairs Pittsburgh Healthcare system, Pittsburgh, Pennsylvania, USA.
Publications dans "Protein-arginine N-methyltransferases" :
Kong Chen
2 publications dans cette catégorie
Affiliations :
- Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Publications dans "Protein-arginine N-methyltransferases" :
Yingze Zhang
2 publications dans cette catégorie
Affiliations :
- Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Publications dans "Protein-arginine N-methyltransferases" :
Sources (10000 au total)
Hypertension in Cancer Survivors.
With increasing survival after cancer treatment, there is a need for long-term management of risk factors and chronic medical conditions to realize the full benefit of improvement of outcomes. Hyperte... A lot of newer anti-cancer therapies have been implicated in the development or worsening of hypertension. We summarize the latest data, explore associations between these therapies and hypertension, ...
Survival of cancer survivors with a new pancreatic cancer diagnosis.
Persons newly diagnosed with pancreas cancer and who have survived a previous cancer are often excluded from clinical trials, despite limited evidence about their prognosis. We examined the associatio... This US population-based cohort study included older adults (aged ≥66 years) diagnosed with pancreas cancer between 2005 and 2015 in the linked Surveillance, Epidemiology, and End Results-Medicare dat... Of 32,783 patients, 18.7% were previously diagnosed with another cancer. The most common previous cancers included prostate (29.0%), breast (18.9%), or colorectal (9.7%) cancer. More than half of prev... Given nearly equivalent survival compared to those without previous cancer, cancer survivors newly diagnosed with pancreas cancer should be considered for inclusion in pancreas cancer clinical trials....
Sleep disturbances among cancer survivors.
We investigated sleep disturbances among cancer survivors compared to similarly aged women without cancer history.... We identified 2067 women with a history of cancer other than breast or non-melanoma skin cancer at enrollment in the Sister Study, a US-wide cohort of women with a family history of breast cancer. Can... At enrollment, cancer survivors were on average 13.8 years (range=0, 62) from diagnosis. After adjustment for age at enrollment and depression, diabetes, hypertension, and menopausal status prior to t... Addressing sleep disturbances may improve well-being for cancer survivors....
Psychological and sexual problems of cancer survivors.
To explore: 1) the unmet needs of breast cancer patients; 2) the sexual needs experienced by breast cancer survivors; 3) the experiences of cancer patients at the time of relapse, including the biopsy... Interpretative phenomenological qualitative research by conducting direct in-depth interviews with participants who met the inclusion criteria. Sample analyzed were breast cancer survivors who had exp... Themes identified for breast cancer patients with unmet needs were i) overcoming health problems in breast cancer survivors; ii) need to access the best health services; iii) women's unmet information... Health-related problems of breast cancer survivors, such as fatigue and fear of cancer recurrence, can lead them to have trouble with social relationships, question their spirituality, and struggle wi...
Online nutrition information for cancer survivors.
This research aims to systematically review a comprehensive sample of websites (English-language) that provide information on nutrition after cancer treatment.... In consultation with cancer survivors and experts, we developed search strings for an internet search (incognito mode in Google Chrome) to be completed in six English-speaking countries (Ireland, the ... Initially, 720 links were found, with 159 eligible for inclusion. Those eligible for review were charity/support/non-governmental organisation weblinks (49.1%) that originated in the United States (42... Cancer survivors seeking nutrition information online may encounter difficulty locating advice, and where they do, it is unlikely to contain guidance on implementation into day-to-day life. This is co...
Management of Breast Cancer Survivors by Gynecologists.
Breast cancer patients commonly present to their OBGYN during the process of diagnosis and treatment of breast cancer both for specific gynecologic needs and for primary care follow up. These patients...
Fear of Cancer Recurrence in Adult Survivors of Childhood Cancer.
Fear of cancer recurrence is common among survivors of adult-onset cancer and associated with increased distress, functional impairment, and health care utilization. However, little is known about the... To characterize the prevalence of and risk factors for clinically significant fear of cancer recurrence in adult survivors of childhood cancer.... This cross-sectional investigation included participants recruited from the Childhood Cancer Survivor Study, a retrospective cohort study of long-term childhood cancer survivors treated at 31 institut... Clinically significant fear of cancer recurrence was assessed via the Fear of Cancer Recurrence Inventory-Short Form. Poisson regression models estimated prevalence ratios (PRs) with 95% CIs adjusted ... The final sample included 229 adult survivors of childhood cancer (115 female [50.2%]; mean [SD] age, 39.6 [9.9] years; mean [SD] time since diagnosis, 31.7 [8.4] years). Among survivors, 38 (16.6%; 9... Decades following treatment, one-third of childhood cancer survivors in this study reported elevated fear their cancer will recur or a subsequent malignant neoplasm will develop. Findings suggest that...
Financial toxicity in thyroid cancer survivors.
Financial burden and distress are high in patients with thyroid cancer. However, little has been done to evaluate potential interventions to mitigate financial toxicity in survivors. This review will ... Thyroid cancer incidence has nearly tripled in the past decades, and cost of treatment is predicted to rise more than other cancers over the next decade. With mean age of diagnosis at 51 years, most p... Thyroid cancer survivors have high rates of financial toxicity, and there remains need for longitudinal studies to evaluate how financial burden may change during the treatment process while also asse...
Needs assessment of cancer survivors in Alaska.
Little is known about cancer survivors' needs in Alaska. To address this knowledge gap, the Alaska Cancer Partnership conducted a needs assessment survey; our objectives were to identify unmet needs o... Cancer survivors were identified using data from the Alaska Cancer Registry. A random sample of 2,600 individuals was selected to receive the survey, which assessed unmet needs across the following do... We received 335 survey responses, for a response of 13.7%. Only 29.9% of cancer survivors expressed that all their needs were met. The most highly ranked unmet needs were as follows: help to reduce st... This assessment provided some of the first information regarding the needs of Alaska's cancer survivors. These results will be used by Alaska Cancer Partnership members across the state to inform heal...